ENHANCEMENT OF PRAZOSIN

Abstract: This invention relates to the synergistic enhancement of certain antihypertensives by the conjunctive use of certain cardiotonic agents. More specifically, this invention relates to the enhancement of the blood pressure lowering effect achieved with alpha₁-adrenoceptor antagonists by the conjunctive administration of cardiotonic agents possessing the ability to specifically inhibit cyclic AMP-phosphodiesterase.

Description: This invention relates to the synergistic enhancement of certain antihypertensives by the conjunctive use of certain cardiotonic agents. More specifically, this invention relates to the enhancement of the blood pressure lowering effect achieved with alpha₁-adrenoceptor antagonists by the conjunctive administration of cardiotonic agents possessing the ability to specifically inhibit cyclic AMP-phosphodiesterase. Still more specifically this invention relates to the synergistic enhancement of the antihypertensive effect of prazosin and prazosin-like compounds by the conjunctive administration of cardiotonic agents which are specific inhibitors of cardiac high affinity cyclic AMP-phosphodiesterase. These inhibitors are also known and identified as F-III PDE or Type 4 PDE inhibitors. Prazosin, the hydrochloride salt of 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furoyl) piperazine, is the only commercially marketed compound of its type. Its exact mechanism of action is not precisely understood, but it is well known that it is unlike conventional alpha blockers in that it causes a decrease in total peripheral resistance related to the blockade of postsynaptic alpha₁- adrenoceptors. Other functionally equivalent agents, e.g., trimazosin, amiquinsin, leniquinsin, quinazosin appear to possess the same type of mechanism of action as does prazosin and, as functionally equivalent alpha₁-adrenoceptor antagonists, are included within the scope of this application. The cardiotonic agents which synergistically enhance the antihypertensive effect of prazosin, and other alpha₁-adrenoceptor blocking agents, are those compounds which normally exert their positive ionotropic effects by selective inhibition of the specific molecular form of cardiac cyclic AMP-phosphodiesterase. Generally these are identified as cardiac cyclic AMP-phosphodiesterase high affinity cyclic AMP, F-III or TYPE 4 PDE inhibitors. Further, although there is no unaminity of thought as to the specific pharmacophore required for these selective inhibitors of cardiac cyclic AMP-phosphodiesterase, such compounds generally possess (1) the presence of a strong dipole (carbonyl) at one end of the molecule, (2) an adjacent acidic proton, (3) a methyl-sized lipophilic space, (4) a relatively flat overall topography and (5) a basic or hydrogen bond acceptor site opposite the dipole. These general characteristics are associated with those cardiotonic agents possessing the ability to selectively inhibit Type 4 PDE and which are generally associated with the pharmacophores possessed by such compounds as amrinone, enoximone, 4,5-dihydro-6-[4-(1H-imidazol-1-yl)-phenyl]-5-methyl-(2H)-pyridazinone, piroximone, milrinone, isomazole, OPC 8212 (Otsuka), RO-13-6438 (Roche), imazadan (Warner Lambert), ARL-57 (Tomae), Sulmazole, UD-CG-115 (Boeringer Ingleheim), UK-36,327 (Pfizer), UK-31,557, USV-2776 (U.S.V. Rohr), pimobendane and any other specific inhibitor of cyclic AMP-phosphodiesterase. This type of compound is the type of compound that selectively inhibits cyclic AMP-phosphodiesterase and as such is inclined within the scope of compounds which synergistically enhance the antihypertensive effect of alpha₁-adrenoceptor blocking agents such as prazosin and trimazosin. In general, the specific cyclic AMP-phosphodiesterase inhibitors of this invention, (i.e., the above-described cardiotonic agents) when conjunctively administered with prazosin to effect their synergistic activity, are administered at about the threshold dose to exert a blood pressure lowering effect, i.e., the minimum dose it takes to exert a statistically significant lowering of blood pressure. This threshold dose is readily determined by standard laboratory methodology. For example, assays such as the Spontaneously Hypertensive Rat and the Anesthesized Dog for testing blood pressur e effects may readily be employed to determine the threshold dose for lowering blood pressure. The threshold dose may also be approximately calculated from an in vitro IC₅₀ value. For this purpose the in vitro IC₅₀ value is the micromolar quantity of compound needed to effect a 50 % inhibition of the activity of cyclic AMP-phosphodiesterase on one (1) micromolar quantity of substrate. This IC₅₀ value, when multiplied by the appropriate fraction for intravenous and oral administrations will yield the dosage range, in mg per kg of body weight, necessary to effect its synergism with prazosin. On the basis of spontaneously hypertensive rat data the multiplying factor is 1/10 to 1 for the intravenous dose and 1 to 10 for the oral dose. On the basis of the anesthesized dog data the multiplying factor is 1/100 to 1/3 for the intravenous dose and 1/3 to 2 for the oral dose. On the basis of projected human doses the multiplying fraction is also 1/100 to 1/3 for intravenous dosing but 1/20 to 1/2 for oral dosing. For example, in the case of peroximone, the in vitro IC₅₀ value is 26 micromolar. Thus the dose range of peroximone to achieve synergism with prazosin in the SHR assay would be 2.6 to 26 mg/kg of body weight on intravenous administration and 26 to 260 mg/kg on oral administration. Results demonstrating synergy are shown in Tables 1 and 2. Analogous calculations may be made with data from dog studies and projected human doses. Table 1 shows the synergistic results of piroximone and prazosin. In the Table, line A shows the results of the control which is the vehicle administered at an oral dose of 5 ml/kg (using 28 animals). Line B shows the results of piroximone when administered at an oral dose of 25 mg/kg (using 12 animals). Line C shows the results of prazosin when administered at an oral dose of 0.1 mg/kg (using 24 animals). Line D shows the results of the combination of piroximone (25 mg/kg) and prazosin (0.1 mg/kg) administered orally (using 24 animals). Table 2 shows the synergistic results of amrinone and prazosin. In the Table, line A shows the results of the control which is the vehicle administered at an oral dose of 5 ml/kg (using 12 animals). Line B shows the results of amrinone when administered at an oral dose of 55 mg/kg (using 12 animals). Line C shows the results of prazosin when administered at an oral dose of 0.1 mg/kg (using 12 animals). Line D shows the results of the combination of amrinone (55 mg/kg) and prazosin (0.1 mg/kg) administered orally (using 12 animals). It is preferable to administer the lowest amount of cyclic AMP-phosphodiesterase inhibitor in combination with the normal antihypertensive dose of prazosin. Further enhancement of the antihypertensive effect of prazosin may be achieved by increasing the amount of the inhibitor of the cyclic AMP-PDE. In the administration of the selective Type IV PDE inhibitors to enhance the antihypertensive effect of the alpha₁-adrenoceptor blocking agents, it is preferred to co-administer the two agents, but the enhancement will take place so long as it is administered to the patient while the alpha₁-adrenoceptor blocking agent is biologically available to effect its antihypertensive action. The synergistic effect will permit a lowering of the dose of the prazosin to avoid any untoward side effects and/or will permit a more effective blood pressure lowering effect, i.e., it will help stabilize the patient to normotensive conditions. Additionally, the combination will improve cardiac function in patients with congestive heart failure, particularly those suffering with hypertension.

Claims: 1. Pharmaceutical composition for the treatment of hypertension comprising an alpha₁-adrenoceptor antagonist and an effective amount of a cardiotonic agent capable of specifically inhibiting cardiac high affinity cyclic AMP-phosphodiesterase. 2. The composition according to claim 1 wherein the alpha₁-adrenoceptor antagonist is prazosin. 3. The composition of claim 2 wherein the cardiotonic agent is enoximone. 4. The composition of claim 2 wherein the cardiotonic agent is amrinone. 5. The composition of claim 2 wherein the cardiotonic agent is 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-5-methyl-(2H)-pyridazinone.< LIT> 6. The composition of claim 2 wherein the cardiotonic agent is piroximone. 7. The composition of claim 2 wherein the cardiotonic agent is imazadan. 8. The composition of claim 2 wherein the cardiotonic agent is isomazole. 9. The use of a cardiotonic agent capable of specifically inhibiting cardiac high affinity cyclic AMP-phosphodiesterase for the production of a medicament for enhancing the effect of an α-adrenoceptor antagonist.

Inventors: DAGE, RICHARD C.
Applicants: MERRELL DOW PHARMACEUTICALS INC.
Application year: 1987
Main classification: A61K45
IPC codes: A61K31, A61K45, A61P25, A61P9, A61P43